Novozymes A/S (NVZMY) News Today $57.26 +0.73 (+1.29%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Comparing Novozymes A/S (OTCMKTS:NVZMY) & Creative Medical Technology (NASDAQ:CELZ)November 21 at 2:07 AM | americanbankingnews.comNovozymes A/S (OTCMKTS:NVZMY) Upgraded by Barclays to Strong-Buy RatingBarclays raised shares of Novozymes A/S to a "strong-buy" rating in a research report on Monday.November 20 at 6:14 AM | marketbeat.comNovonesis Reports Strong Q3 Growth in 2024November 10, 2024 | markets.businessinsider.comNovonesis: Underperformance In Price, But Now I'm Buying (Rating Upgrade)November 8, 2024 | seekingalpha.comNovozymes A/S (OTCMKTS:NVZMY) Stock Passes Below 50 Day Moving Average - What's Next?Novozymes A/S (OTCMKTS:NVZMY) Stock Passes Below 50-Day Moving Average - Time to Sell?November 5, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Short Interest UpdateNovozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,400 shares, a decrease of 22.2% from the September 30th total of 1,800 shares. Based on an average daily volume of 21,200 shares, the short-interest ratio is presently 0.1 days.October 27, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Stock Rating Lowered by CitigroupCitigroup lowered shares of Novozymes A/S from a "neutral" rating to a "sell" rating in a research note on Thursday.October 17, 2024 | marketbeat.comShort Interest in Novozymes A/S (OTCMKTS:NVZMY) Drops By 73.5%Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,800 shares, a decline of 73.5% from the September 15th total of 6,800 shares. Based on an average daily trading volume, of 16,300 shares, the short-interest ratio is presently 0.1 days.October 10, 2024 | marketbeat.comBerenberg Bank Upgrades Novozymes A/S (OTCMKTS:NVZMY) to "Strong-Buy"Berenberg Bank upgraded shares of Novozymes A/S to a "strong-buy" rating in a research note on Tuesday.September 26, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Sets New 1-Year High After Dividend AnnouncementNovozymes A/S (OTCMKTS:NVZMY) Sets New 12-Month High After Dividend AnnouncementAugust 30, 2024 | marketbeat.comWhat Wall Street expects from Novozymes A-S (B)'s earningsAugust 27, 2024 | markets.businessinsider.comNovozymes A-S (B) Un earnings: here's what to expectAugust 27, 2024 | markets.businessinsider.comNovozymes A/S B (NSISb)July 19, 2024 | investing.comNovozymes A/S (NSISBC.XC)July 19, 2024 | finance.yahoo.comNovozymes A/S (OTCMKTS:NVZMY) Sees Large Increase in Short InterestNovozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,800 shares, an increase of 27.3% from the May 31st total of 2,200 shares. Based on an average daily volume of 19,500 shares, the short-interest ratio is presently 0.1 days.June 30, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Stock Price Crosses Above 50-Day Moving Average of $59.19Novozymes A/S (OTCMKTS:NVZMY) Shares Pass Above 50-Day Moving Average of $59.19June 21, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Stock Crosses Above 50 Day Moving Average of $58.63Novozymes A/S (OTCMKTS:NVZMY) Share Price Crosses Above 50 Day Moving Average of $58.63June 13, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Share Price Crosses Above Fifty Day Moving Average of $58.28Novozymes A/S (OTCMKTS:NVZMY) Stock Crosses Above Fifty Day Moving Average of $58.28June 5, 2024 | marketbeat.comNovonesis AS's Dividend AnalysisApril 30, 2024 | finance.yahoo.comNovozymes A/S Plans Dividend of $0.19 (OTCMKTS:NVZMY)Novozymes A/S (OTCMKTS:NVZMY) declared a dividend on Thursday, April 11th. Shareholders of record on Thursday, May 2nd will be given a dividend of 0.1853 per share by the biotechnology company on Monday, May 20th. The ex-dividend date is Wednesday, May 1st.April 11, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Reaches New 1-Year High at $61.86Novozymes A/S (OTCMKTS:NVZMY) Hits New 12-Month High at $61.86March 20, 2024 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Sees Large Drop in Short InterestNovozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 29th, there was short interest totalling 1,300 shares, a decrease of 79.7% from the February 14th total of 6,400 shares. Based on an average daily trading volume, of 97,000 shares, the days-to-cover ratio is presently 0.0 days.March 12, 2024 | marketbeat.comDuPont lifts dividend by ~6% to $0.38/share; initiates $1B stock buyback planFebruary 6, 2024 | msn.comDuPont’s stock jumps on dividend hike, stock buybackFebruary 6, 2024 | seekingalpha.comNovozymes A/S: Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completedFebruary 2, 2024 | finanznachrichten.deNovozymes A/S (OTCMKTS:NVZMY) Announces Earnings ResultsNovozymes A/S (OTCMKTS:NVZMY - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.36 EPS for the quarter, missing analysts' consensus estimates of $0.47 by ($0.11). Novozymes A/S had a net margin of 17.98% and a return on equity of 22.64%. The company had revenue of $664.46 million for the quarter.February 2, 2024 | marketbeat.comSettlement of the combination of Novozymes and Chr. Hansen Holding successfully completedFebruary 2, 2024 | finance.yahoo.comNovozymes A-S (B) is about to announce its earnings — here's what to expectJanuary 31, 2024 | markets.businessinsider.comThe combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partnerJanuary 29, 2024 | finance.yahoo.comMajor shareholder announcementJanuary 29, 2024 | finance.yahoo.comNovozymes A/S (OTCMKTS:NVZMY) Sees Large Growth in Short InterestNovozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,100 shares, a growth of 320.0% from the December 15th total of 500 shares. Based on an average trading volume of 21,600 shares, the days-to-cover ratio is currently 0.1 days.January 12, 2024 | marketbeat.comNovozymes A/S: Novozymes and Chr. Hansen announce name of future combined company; NovonesisDecember 13, 2023 | finanznachrichten.deNovozymes and Chr. Hansen announce name of future combined company; NovonesisDecember 13, 2023 | finance.yahoo.comNovozymes A/S goes ex-dividend tomorrowOctober 19, 2023 | msn.comNovozymes A/S: Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlookAugust 9, 2023 | finanznachrichten.deNovozymes A/S (OTCMKTS:NVZMY) Given Consensus Recommendation of "Hold" by BrokeragesNovozymes A/S (OTCMKTS:NVZMY - Get Rating) has been assigned an average recommendation of "Hold" from the eight brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one hMay 4, 2023 | marketbeat.comNovozymes A/S: Novozymes delivers stronger than expected Q1 resultsApril 26, 2023 | finanznachrichten.deNovozymes's Earnings: A PreviewApril 25, 2023 | msn.comNovozymes A/S (OTCMKTS:NVZMY) Short Interest Up 1,533.3% in MarchNovozymes A/S (OTCMKTS:NVZMY - Get Rating) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 4,900 shares, a growth of 1,533.3% from the March 15th total of 300 shares. Based on an average trading volume of 31,300 shares, the days-to-cover ratio is presently 0.2 days.April 14, 2023 | marketbeat.comNovozymes A/S (OTCMKTS:NVZMY) Given Consensus Recommendation of "Hold" by AnalystsShares of Novozymes A/S (OTCMKTS:NVZMY - Get Rating) have earned a consensus recommendation of "Hold" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold ratinApril 9, 2023 | marketbeat.comNovozymes A/S: Novozymes' and Chr. Hansen's shareholders approve combination to create a leading global biosolutions partnerMarch 30, 2023 | finanznachrichten.deCombination between Novozymes and Chr. Hansen approved by Novozymes’ shareholdersMarch 30, 2023 | finance.yahoo.comNovozymes, Chr. Hansen Merger Cleared by US Antitrust RegulatorsMarch 28, 2023 | marketwatch.comHow is Novozymes OneHealth leading the probiotic market segment in FIC2023?March 16, 2023 | finance.yahoo.comNovozymes A/S (OTCMKTS:NVZMY) Receives Consensus Recommendation of "Hold" from AnalystsShares of Novozymes A/S (OTCMKTS:NVZMY - Get Rating) have been given an average rating of "Hold" by the ten brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rMarch 15, 2023 | marketbeat.comNovozymes swells land holdings in Franklin CountyMarch 1, 2023 | bizjournals.comNo Major Surprises in Novozymes’ Q4 2022 ResultsFebruary 25, 2023 | morningstar.comNovozymes A/S PT Lowered to DKK425 at BerenbergFebruary 20, 2023 | investing.comNovozymes A/S (NVZMF) Q4 2022 Earnings Call TranscriptJanuary 26, 2023 | seekingalpha.comNovozymes A/S: Novozymes delivers historically strong full-year resultsJanuary 26, 2023 | finanznachrichten.de Get Novozymes A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. NVZMY Media Mentions By Week NVZMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVZMY News Sentiment▼1.300.52▲Average Basic Materials News Sentiment NVZMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVZMY Articles This Week▼30▲NVZMY Articles Average Week Get Novozymes A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies argenx News Today BioNTech News Today Biogen News Today Moderna News Today Neurocrine Biosciences News Today Vaxcyte News Today Bio-Techne News Today Exelixis News Today Revolution Medicines News Today Qiagen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NVZMY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novozymes A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novozymes A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
